Login to Your Account


Cardiorentis' Heart Failure Trial Backed by $131M Investment

By Nuala Moran
Staff Writer

Wednesday, December 5, 2012
LONDON – The secretive backers of Cardiorentis Ltd. prefer to remain anonymous, but they obviously are expecting to see the name of the company's main asset, Ularitide, in lights, having made a €100 million (US$130.6 million) investment to put the product through a Phase III trial in treating 2,116 patients with acute heart failure.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription


»